Zacks Investment Research lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a sell rating in a research note issued to investors on Monday morning.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

AUPH has been the topic of a number of other research reports. Leerink Swann upped their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an outperform rating in a research note on Monday, October 23rd. HC Wainwright restated a buy rating and issued a $12.00 target price (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research note on Monday, October 30th. Cantor Fitzgerald restated a buy rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. BidaskClub lowered shares of Aurinia Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a research note on Friday, November 17th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $10.59.

Shares of Aurinia Pharmaceuticals (AUPH) opened at $5.06 on Monday. Aurinia Pharmaceuticals has a 12 month low of $3.17 and a 12 month high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The business’s revenue was up .0% on a year-over-year basis. equities analysts forecast that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUPH. Goldman Sachs Group Inc. raised its stake in Aurinia Pharmaceuticals by 357.3% during the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock worth $5,373,000 after acquiring an additional 684,816 shares during the period. Balyasny Asset Management LLC raised its stake in Aurinia Pharmaceuticals by 66.7% during the second quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $3,065,000 after acquiring an additional 200,000 shares during the period. Redmile Group LLC raised its stake in Aurinia Pharmaceuticals by 137.0% during the second quarter. Redmile Group LLC now owns 332,310 shares of the biotechnology company’s stock worth $2,037,000 after acquiring an additional 192,067 shares during the period. Ameriprise Financial Inc. acquired a new stake in Aurinia Pharmaceuticals during the second quarter worth about $928,000. Finally, Swiss National Bank acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $421,000. Hedge funds and other institutional investors own 28.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/09/aurinia-pharmaceuticals-auph-downgraded-by-zacks-investment-research.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.